TNF and VEXAS syndrome: Anti-interleukin (IL)-1, anti-IL-6, and anti-tumor necrosis factor (TNF) agents are the most widely used bDMARDs in VEXAS patients to date (Borie et al., 2023; Mascaro et al., 2023; Johansen et al., 2023; Oka et al., 2024; Vu et al., 2023).